Trial Profile
A Randomized Phase 2 Trial of AM0010 in Combination With Nivolumab vs. Nivolumab Alone as Second-Line Therapy in Subjects With Stage IV / Metastatic Wild Type Non-Small Cell Lung Cancer and Low Tumor Expression of PD-L1
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Ilodecakin (Primary) ; Nivolumab
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms Cypress 2
- Sponsors ARMO Biosciences; Eli Lilly and Company
- 06 Nov 2020 Results of CYPRESS-1 and CYPRESS-2 published in the Journal of Thoracic Oncology
- 31 May 2020 Exploratory pharmacodynamic results presented at the 56th Annual Meeting of the American Society of Clinical Oncology
- 04 May 2020 Status changed from active, no longer recruiting to discontinued.